AzTrials
AzTrials

Endometrial Receptivity and Success Rate of IVFNCT01809509

Pilot Study on Molecular Quantitation and Sequencing of Endometrial Cytokines Gene Expression and Their Effect on the Outcome of In-vitro Fertilization (IVF) Cycle

An observational study of Endometrial Receptivity and Success Rate of IVF, run by Cairo University at 2 sites in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Pilot study on molecular quantitation and sequencing of endometrial cytokines gene expression and their effect on the outcome of in-vitro fertilization (IVF) Cycle Read more about this study

Who is it for?
Ages 23 to 35 years, women onlyHealthy volunteers can take part
What is being tested?
Endometrial biopsy
Type of treatment
Surgery or procedure
How many people
15 participants
Where
2 sitesEgypt
Study dates
Jan 2012to Nov 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 23 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: those under going IVF using standard protocol

Who may be able to join

  • FSH LESS THAN 10 ,

Who cannot join

  • NO SEVER MALE FACTOR no endometriosis , DM or previous uterine surgery .

Trial locations and contacts

2 sites in 1 country.

Egypt2 sites
  • Olfat Nooh Riad Ali

    Cairo, 14777

  • IVF centre

    Cairo

Other trials in Egypt

About this study

Official title: A Prestudy of Impact of Cytokines and Gene Expression on Outcome of IVF

Pilot study on molecular quantitation and sequencing of endometrial cytokines gene expression and their effect on the outcome of in-vitro fertilization (IVF) Cycle

Read the detailed description

The study will be performed

in the Cairo IVE Unit; Faculty of medicine Cairo University on 15 cases. Inclusion criteria: age 23 -35, FSH less than 10 no previous uterine operations, no history of poor response in previous IVF no sever male factor no endometriosis and uterine factor are excluded . no diabetes mellitus and antral follicle count (AFC) > 5 undergoing IVF using standard long protocol.

All patients will give their informed consent to participate in the study. Endometrial tissue samples will be taken on the day of oocyte retrieval using soft suction plastic catheter. The menstrual blood of 10 women with regular menstrual cycles and with no apparent endometrial dysfunction was taken as control samples. The study protocol and informed consents were approved by the Human Ethics Committee of IVF department .of Kasar Ini hospital

Total RNA isolation: Endometrial biopsies and menstrual control blood will be lysed by RLT buffer (QIAGEN, Germantown, MD). The lysates further prepared for total RNA extraction using the RNeasy mini kit (QIAGEN, Germantown, MD) according to the manufacturer's instructions. The RNA extract stored at -80ºC until future use. RNA purity, yield, and concentration will be determined through dual spectrophotometry (Beckman, USA), and 1μg of RNA run on a 1% agarose gel (Roche, Castle Hill, Australia) to ensure integrity of the RNA. Quantitative RT-PCR (qRT-PCR): Reverse transcriptase (RT) reaction mixture using High Capacity Reverse Transcriptase kit (Applied Biosystems, USA) containing: 1 μg total RNA from each sample for cDNA synthesis, 0.5 μg random primer, 5×RT buffer, 2.5 mmol/L dNTP, 20 U RNase inhibitor and 200 U MMLV reverse transcriptase in a total volume of 25 μl was incubated at 37ºC for 60 minutes, then heated to 95 ºC for 5 minutes to inactivate MMLV. RT will be followed by qPCR, 50 ng of cDNA were added to 5 X Fast-Start SYBR green master mix with Rox (Roche Diagnostics, Indianapolis, IN) and 200 ng of primer mix (Sigma). The reaction will be carried out in micro optical plates (Applied Biosystems) and analyzed using StepOne real-time 203 PCR system (Applied Biosystems). The PCR running method was as follows: 10 minutes at 950C for enzyme activation followed by 40 cycles of 15 seconds at 950C, 20 seconds at 550C and 30 second at 720C for the amplification step. The primers used in the qRT-PCR evaluation specific for target genes (table 1). Relative mRNA expression will be calculated by the comparative cycle threshold method . as outlined in the manufacturer's user manual with GAPDH house-keeping gene. The fluorescence was plotted versus PCR cycle number for reaction and each sample indicated. Serum hormonal levels assay: FSH, LH and E2 were estimated by ELISA according to instructions of manufacturers. DNA purification and sequencing analysis: IL-11 and LIF genes analyzed by direct sequencing of the PCR products using SEQr kit. (Applied Biosystems), according to manufacturer's protocol. PCR products will be purified using the QIAquick Gel Extraction Kit (QIAGEN). The relevant purified DNA samples of all the cases and controls will be amplified and sequenced using automated sequencing with the aid of a Big Dye Terminator Sequencing Kit (PE/Applied Biosystems, Foster City, CA). The samples will be run in an automated sequencer ABI Prism 310 Avant (PE/Applied Biosystems).. All samples will be sequenced twice to ensure the results.

Statistical analysis: Data will be statistically described in terms of mean standard deviation , median and range. Comparison between women who could achieve pregnancy and those who didn't was done using Mann Whitney U test for independent samples. Correlation between various variables was done using Spearman rank correlation equation for non-normal variables.

Being tested
Endometrial biopsy
Keywords
CYTOKINES , IL11 IL6 IMLANTATION RATE IVF.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endometrial biopsyProcedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. relation between IL11 AND IL6 PRESENCE AND GENE EXPRESSION AND SUCCESS OF IVF

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2013 (estimated)
  2. Study startJan 2012
  3. Primary completionJun 2013 (estimated)
  4. Study completionNov 2013 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01809509
Sponsor's protocol ID
FDAAA
Status last verified
Mar 2013
First submitted
9 Mar 2013
Last updated
12 Mar 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Endometrial Receptivity and Success Rate of IVF, run by Cairo University at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

relation between IL11 AND IL6 PRESENCE AND GENE EXPRESSION AND SUCCESS OF IVF (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in